Clio Harper, MD
Ophthalmology · Austin, TXNPI 1013989706
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.4%), other and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Regeneron at 50.2% of the total. Reporting peaked in 2020 at $7,004 and has fallen 93.7% since, to $444 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $291.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$7K
- US Retina LLC$4K
- AbbVie$760
- Regeneron Healthcare Solutions, Inc.$424
- Genentech, Inc.$229
- Carl Zeiss Meditec, Inc.$176
- plus $741 from 7 others
Across 22 payments — averaging $1018.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$17K
- Regeneron$5K
What the payments were for
- Consulting fees$6,48048%
- Grants$5004%
- Food & beverage$1,89914%
- Gifts$1761%
- Ownership interest$1,56012%
- Other$2,77221%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 5 | $6,725 |
| US Retina LLC | 7 | $4,331 |
| AbbVie(2 entities) | 4 | $760 |
| Regeneron Healthcare Solutions, Inc. | 13 | $424 |
| Genentech, Inc. | 2 | $229 |
| Carl Zeiss Meditec, Inc. | 1 | $176 |
| Alimera Sciences, Inc. | 2 | $167 |
| Novartis | 3 | $164 |
| Alcon | 2 | $142 |
| Apellis Pharmaceuticals, Inc. | 1 | $94 |
| Bausch & Lomb Americas Inc. | 2 | $81 |
| Genentech USA, Inc. | 3 | $64 |
| Neurotech Pharmaceuticals, Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,386 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 19 | $6,754 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Austin
- Chirag JhaveriAustin$240K
- Sheila BarbarinoAustin$232K
- Aaron RollerAustin$202K
- Philip StoreyAustin$161K
- Robert WongAustin$113K
- Farhan IrshadAustin$111K
- Edward WoodAustin$110K
- Ryan YoungAustin$105K
- Steven DellAustin$94K
- Shelley GhafooriAustin$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.